Himanshu Nagar

The Latest Radiation Therapy for Prostate Cancer: What Every Man Should Know It can be hard to understand all the various radiation therapy options for prostate cancer. Here, we explain.

Radiation therapy for prostate cancer is more precise, convenient, and personalized than ever before. From #SBRT to MRI-guided and adaptive approaches, MSK experts are leading advances that improve outcomes and protect quality of life for patients with #prostatecancer. ⬇️

NRG-GU015, the "ARCHER" study, recently activated! We interviewed study PI, Scott Delacroix, and co-PI @himanshunagarmd.bsky.social on this phase 3 study of adaptive radiation and chemotherapy for muscle invasive #bladdercancer. Watch the full interview here: youtu.be/qCc-htw39to

ARCHER trial opens enrollment to assess shorter duration of radiation therapy for MIBC The ARCHER trial is seeking to determine whether ultra-hypofractionated radiotherapy is non-inferior to hypofractionated radiotherapy in terms of bladder-intact event-free survival.

Enrollment in now open in the phase 3 ARCHER trial, which is assessing the safety and efficacy of a shorter duration of radiation therapy in patients with muscle invasive bladder cancer. www.urologytimes.com/view/archer-...

PRESS RELEASE: NRG Oncology Opens New “ARCHER” Clinical Trial (NRG-GU015) Testing a Shorter Treatment Duration of Radiation Therapy for Muscle Invasive Bladder Cancer - Read more: ow.ly/6lyF50WG0GN
@himanshunagarmd.bsky.social
@mskcancercenter.bsky.social

A Randomized Controlled Phase 2 Trial Comparing Salvage Radiotherapy for Prostate Cancer Delivered in 4 Versus 2 Weeks (SHORTER): Acute Genitourinary and Gastrointestinal Patient-reported Outcomes at ... Some patients undergoing prostatectomy develop biochemical recurrence or have persistently detectable prostate-specific antigen level. Salvage radioth…

A Randomized Controlled Phase 2 Trial Comparing Salvage Radiotherapy for Prostate Cancer Delivered in 4 Versus 2 Weeks (SHORTER): Acute Genitourinary and Gastrointestinal Patient-reported Outcomes at a Single Institution @mskcancercenter.bsky.social @weillcornell.bsky.social

Stereotactic body radiotherapy for oligoprogressive disease in androgen suppressed prostate cancer: Primary endpoint analysis of the TRAP trial Optimal management of oligoprogressive prostate cancer whilst on androgen receptor pathway inhibitors (ARPi) is not known. The **** trial tests the ro…

TRAP trial results now out @ijrobp.bsky.social funded by @prostatecanceruk.bsky.social Men oligoprogressing on Abi/Enza for CRPC, nearly 40% progression-free 1 year after SBRT. No significant side effects due to radiotherapy.

www.sciencedirect.com/science/arti...

And here are the point and counterpoint opinions:

www.redjournal.org/article/S036...

www.redjournal.org/article/S036...

Last week, the 19th MR-Linac Consortium meeting convened in Singapore. It was great to see such high energy and strong global community come together to share insights on new clinical and technical innovations. Special thanks to all the presenters and attendees, see you next time! #MRgRT #innovation

PEACE-1: rPFS for low volume mHSPC

PEACE-1 trial of prostate radiotherapy in mHSPC. Improvement in rPFS when used in addition to ADT and abiraterone. Medsky. Oncsky.

Proud of my sister. Calm, deliberative, and forward focused. @blandro.bsky.social

youtube.com/watch?v=w2ft...

Free learning opportunity! Try your ✋at outlining the prostate and urethra on MRI. See how your answer overlays on expert panel's consensus contours.

#radonc #radiology #nucmed #urology welcome. Trainees and attendings. Generalists and specialists.

Being done on and off trial (5 Gy x 5 to nodes). Stay tuned for PACE NODES. Allowed on NRG GU 009.

I'm hoping that's true everywhere 😉

Phase 3 Trial of Stereotactic Body Radiotherapy in Localized Prostate Cancer | NEJM Whether stereotactic body radiotherapy (SBRT) is noninferior to conventionally or moderately hypofractionated regimens with respect to biochemical or clinical failure in patients with localized pro...

Hat tip to PACE B as a practice changing or affirming trial in #ProstateCancer for #RadOnc
www.nejm.org/doi/full/10....

MRI Vs CT Guidance for Stereotactic Body Radiotherapy in #ProstateCancer
MIRAGE trial out on European Urology
Results suggest that MRI-guided SBRT offers long-term benefits in reducing toxic effects by allowing for more aggressive margin reduction in treatment planning.

https://buff.ly/4fA8VmA

Run TCS New York City Marathon for Cancer Research | Fred's Team Find out how you can run in the next TCS New York City Marathon as a Fred's Team member and help raise money for pioneering cancer research at MSK.

Fill out an application to run the 2025 #NYCMarathon with
#Fred'sTeam to raise money for cancer research at #MemorialSloanKetteringCancerCenter.